Biomarkers of response to treatment in acromegaly
INTRODUCTION: Medical treatment of acromegaly is based in a `trial and error` approach. First-generation somatostatin receptor ligands (fg-SRL) are prescribed as first-line medical therapy to the vast majority of patients, despite lack of disease control in approximately 60% of patients. However, other drugs used in acromegaly treatment are available (cabergoline, pasireotide and pegvisomant).
AREAS COVERED: In this article, we review and discuss the biomarkers of response to medical treatment in acromegaly.
EXPERT OPINION: Biomarkers for fg-SRL that can already be applied in clinical practice are: gender, age, pretreatment GH and IGF-I levels, cytokeratin granulation pattern, and the expression of somatostatin receptor type 2. Using biomarkers of response could guide treatment towards precision medicine with greater efficacy and lower costs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Expert review of endocrinology & metabolism - 19(2024), 1 vom: 20. Jan., Seite 71-80 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kasuki, Leandro [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acromegaly |
|---|
| Anmerkungen: |
Date Completed 03.01.2024 Date Revised 24.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/17446651.2023.2293107 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365692603 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365692603 | ||
| 003 | DE-627 | ||
| 005 | 20240125232004.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/17446651.2023.2293107 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1270.xml |
| 035 | |a (DE-627)NLM365692603 | ||
| 035 | |a (NLM)38078447 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kasuki, Leandro |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Biomarkers of response to treatment in acromegaly |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.01.2024 | ||
| 500 | |a Date Revised 24.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: Medical treatment of acromegaly is based in a `trial and error` approach. First-generation somatostatin receptor ligands (fg-SRL) are prescribed as first-line medical therapy to the vast majority of patients, despite lack of disease control in approximately 60% of patients. However, other drugs used in acromegaly treatment are available (cabergoline, pasireotide and pegvisomant) | ||
| 520 | |a AREAS COVERED: In this article, we review and discuss the biomarkers of response to medical treatment in acromegaly | ||
| 520 | |a EXPERT OPINION: Biomarkers for fg-SRL that can already be applied in clinical practice are: gender, age, pretreatment GH and IGF-I levels, cytokeratin granulation pattern, and the expression of somatostatin receptor type 2. Using biomarkers of response could guide treatment towards precision medicine with greater efficacy and lower costs | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Acromegaly | |
| 650 | 4 | |a biomarkers | |
| 650 | 4 | |a medical treatment | |
| 650 | 4 | |a precision medicine | |
| 650 | 4 | |a somatostatin receptor ligand | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 700 | 1 | |a Lamback, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Antunes, Ximene |e verfasserin |4 aut | |
| 700 | 1 | |a Gadelha, Mônica R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert review of endocrinology & metabolism |d 2006 |g 19(2024), 1 vom: 20. Jan., Seite 71-80 |w (DE-627)NLM191111503 |x 1744-8417 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2024 |g number:1 |g day:20 |g month:01 |g pages:71-80 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/17446651.2023.2293107 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2024 |e 1 |b 20 |c 01 |h 71-80 | ||